The role of ghrelin in acute versus prolonged critical illness

Completed

Conditions: Critical illness
Not Applicable

Registration Number: ISRCTN49433936

Lead Sponsor: Catholic University Leuven (Katholieke Universiteit Leuven) (Belgium)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 16

Inclusion Criteria

1. Patients admitted to any of the five intensive care units (ICUs)
2. Older than 18 years
3. Age, gender and BMI matched healthy subjects

Exclusion Criteria

1. Age less than 18 years
2. Pre-existing neurological, psychiatric, metabolic, or endocrine disease
3. Intracranial hypertension
4. Intracranial lesions which could influence the hypothalamus-pituitary axis function
5. Gastrectomy
6. Clinically significant liver failure (prothrombin time <30%)
7. Concomitant treatment with thyroid hormones high dose glucocorticoids (>90mg hydrocortisone/day or >18 mg methyl-prednisolone/day), somatostatin, clonidine, dopamine or dopamine antagonist.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concentrations of ghrelin and GH will be measured in each sample.

Secondary Outcome Measures

Name	Time	Method
1. Information obtained from each patient at baseline<br>1.1. Demographic<br>1.2. Diagnostic<br>1.3. Therapeutic<br>1.4. Severity of illness (Acute Physiology and Chronic Health Evaluation [APACHE-II]) (Knaus W.A. et al. Critical Care Medicine, 1985, 13:818-829)<br> 2. Evaluation of trends in organ dysfunction (Sepsis-related Organ Failure Assessment score [SOFA]) (Intensive Care Med. 1996,22:707-10)<br>3. At 06.00h, serum concentrations of the following will be measured: <br>3.1. Insulin-like growth factor I (IGF-I)<br>3.2. IGF-binding protein-1 (IGFBP-1)<br>3.3. IGFBP-3<br>3.4. The acid-labile subunit (ALS)<br>3.5. IGFBP-4<br>3.6. IGFBP-5<br>3.7. Insulin<br>3.8. Leptin<br>3.9. TSH<br>3.10. Cortisol<br>3.11. Adrenocorticotrophic Hormone (ACTH)